A citation-based method for searching scientific literature

F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel, Wallace Akerley, Alfons J M van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia M Vaubel, Gerald P Linette, David Hogg, Christian H Ottensmeier, Celeste Lebbé, Christian Peschel, Ian Quirt, Joseph I Clark, Jedd D Wolchok, Jeffrey S Weber, Jason Tian, Michael J Yellin, Geoffrey M Nichol, Axel Hoos, Walter J Urba. N Engl J Med 2010
Times Cited: 9840



James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier F Ferrucci, Michael Smylie, David Hogg, Andrew Hill, Ivan Márquez-Rodas, John Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S Carlino, Céleste Lebbé, Grant McArthur, Paolo A Ascierto, Gregory A Daniels, Georgina V Long, Lars Bastholt, Jasmine I Rizzo, Agnes Balogh, Andriy Moshyk, F Stephen Hodi, Jedd D Wolchok. N Engl J Med 2019
Times Cited: 1225




List of shared articles



Times cited

Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma.
Jing-Jing Li, Jiu-Hong Wang, Ya Dingv, Dan-Dan Li, Xi-Zhi Wen, Jing-Jing Zhao, Hang Jiang, Xing Liu, Fu-Xue Huang, Xiao-Shi Zhang. J Cancer Res Clin Oncol 2022
5

Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?
Michael Kuske, Maximilian Haist, Thomas Jung, Stephan Grabbe, Matthias Bros. Cancers (Basel) 2022
0

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study.
Li Zhou, Xiaowen Wu, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Lili Mao, Bin Lian, Bixia Tang, Xieqiao Yan,[...]. BMC Cancer 2022
0

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.
Lukas Kraehenbuehl, Chien-Huan Weng, Shabnam Eghbali, Jedd D Wolchok, Taha Merghoub. Nat Rev Clin Oncol 2022
29


Immune checkpoint inhibitors for the treatment of melanoma.
Francesco Sabbatino, Luigi Liguori, Stefano Pepe, Soldano Ferrone. Expert Opin Biol Ther 2022
0

Mesenchymal-epithelial transition factor (MET) immunoreactivity in positive sentinel nodes from patients with melanoma.
Evalyn E A P Mulder, Daniëlle Verver, Thom van der Klok, Calvin J de Wijs, Thierry P P van den Bosch, Maria J De Herdt, Berdine van der Steen, Cornelis Verhoef, Astrid A M van der Veldt, Dirk J Grünhagen,[...]. Ann Diagn Pathol 2022
0

The cure from within? a review of the microbiome and diet in melanoma.
Priyanka Kumar, Danielle Brazel, Julia DeRogatis, Jennifer B Goldstein Valerin, Katrine Whiteson, Warren A Chow, Roberto Tinoco, Justin T Moyers. Cancer Metastasis Rev 2022
0

Resistance Mechanisms to Anti-PD Cancer Immunotherapy.
Matthew D Vesely, Tianxiang Zhang, Lieping Chen. Annu Rev Immunol 2022
0

NeoSplice: a bioinformatics method for prediction of splice variant neoantigens.
Shengjie Chai, Christof C Smith, Tavleen K Kochar, Sally A Hunsucker, Wolfgang Beck, Kelly S Olsen, Steven Vensko, Gary L Glish, Paul M Armistead, Jan F Prins,[...]. Bioinform Adv 2022
0

Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.
Tae Kon Kim, Esten N Vandsemb, Roy S Herbst, Lieping Chen. Nat Rev Drug Discov 2022
0

Metabolic Implications of Immune Checkpoint Proteins in Cancer.
Elizabeth R Stirling, Steven M Bronson, Jessica D Mackert, Katherine L Cook, Pierre L Triozzi, David R Soto-Pantoja. Cells 2022
1

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.
C Robert, K D Lewis, R Gutzmer, D Stroyakovskiy, H Gogas, S Protsenko, R P Pereira, T Eigentler, P Rutkowski, L Demidov,[...]. Ann Oncol 2022
0